Aytu Biopharma, Inc.

As of September 10, 2025, Aytu Biopharma, Inc. is fairly valued with a P/E ratio of 2, a Price to Book Value of 0.35, and an EV to EBITDA ratio of 2.23, outperforming some peers with negative P/E ratios, while its stock has recently outperformed the S&P 500 over the past week and month but lagged in the longer term.

As of May 14, 2025, Aytu Biopharma, Inc. is considered an attractive investment due to its low P/E ratio of 2, an EV to EBITDA ratio of 2.23, a price to book value of 0.35, and a year-to-date return of 16.47%, despite a 31.96% decline over the past year.

As of June 17, 2025, Aytu Biopharma, Inc. shows a mildly bullish trend primarily due to the weekly MACD and KST, despite mixed signals from the RSI, daily moving averages, and monthly indicators.

As of March 2022, Aytu Biopharma, Inc.'s management team includes Mr. Joshua Disbrow as Chairman and CEO, with directors Mr. Steven Boyd, Mr. Ketan Mehta, and independent directors Mr. Gary Cantrell, Mr. Carl Dockery, and Mr. John Donofrio.

Aytu Biopharma, Inc. is a specialty pharmaceutical company focused on prescription products for primary care and pediatrics, with a market cap of $12.16 million and recent net sales of $18 million. Key financial metrics include a P/E ratio of 2.00 and a return on equity of 16.29%.

As of Jun 18, Aytu Biopharma, Inc. has a market capitalization of 12.16 million, with net sales of 69.22 million and a net profit of 1.08 million reported over the last four quarters. As of Jun 24, the company's shareholder's funds were 27.72 million, and total assets were 118.86 million.